Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0000950170-25-025761
Filing Date
2025-02-24
Accepted
2025-02-24 17:00:12
Documents
2
Period of Report
2025-02-20

Document Format Files

Seq Description Document Type Size
1 3 ownership.html 3  
1 3 ownership.xml 3 2195
2 EX-24 evok-ex24.htm EX-24 12937
  Complete submission text file 0000950170-25-025761.txt   16691
Mailing Address 420 STEVENS AVENUE SUITE 230 SOLANA BEACH CA 92075
Business Address 420 STEVENS AVENUE SUITE 230 SOLANA BEACH CA 92075 858-345-1494
Evoke Pharma Inc (Issuer) CIK: 0001403708 (see all company filings)

EIN.: 208447886 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O AYTU BIOPHARMA, INC. 373 INVERNESS PARKWAY, SUITE 206 ENGLEWOOD CO 80112
Business Address
PYSZCZYMUKA GREG (Reporting) CIK: 0001952920 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-36075 | Film No.: 25658004